Menu Back toChallenges and Opportunities in Early Development of RNA Therapeutics

DIA 2021 Global Annual Meeting

Challenges and Opportunities in Early Development of RNA Therapeutics

Session Chair(s)

Philip (P.J.)  Brooks, PhD

Philip (P.J.) Brooks, PhD

  • Deputy Director, Office of Rare Diseases Research
  • National Center for Advancing Translational Sciences (NCATS), NIH, United States
RNA molecules play a variety of important roles in cells, including structural (ribosomal RNA), enzymatic (small nuclear RNA), and information transfer (messenger RNA). The relatively large size and well-known instability of RNA would make it an unlikely vehicle for drug development. However, in recent years, it has become clear that RNA molecules are an emerging as a class of therapeutics of relevance to multiple diseases, most recently including vaccines. In this session, we will be discussing different examples of RNA based therapeutics, as well as some regulatory considerations.
Learning Objective : Describe different types of RNA therapeutics; Discuss some of the unique challenges involved in the production of RNA therapeutics.


Philip  Santangelo

Messenger RNAs as Drugs

Philip Santangelo

  • Professor, Coulter Department of Biomedical Engineering
  • Georgia Institute of Technology & Emory University School of Medicine, United States
Girish R Chopda, PhD

Nonclinical Development of Oligonucleotide Therapeutics

Girish R Chopda, PhD

  • Associate Director, Nonclinical Development
  • Dicerna Pharmaceuticals, United States
Christopher  Saeui, PhD

Regulatory Preclinical Considerations for mRNA Therapeutic Products

Christopher Saeui, PhD

  • Biologist, Pharm/Tox/OTAT, CBER
  • FDA, United States